NO20065012L - Tetrahydronaftyridin-derivater og fremgangsmate for fremstilling av disse - Google Patents

Tetrahydronaftyridin-derivater og fremgangsmate for fremstilling av disse

Info

Publication number
NO20065012L
NO20065012L NO20065012A NO20065012A NO20065012L NO 20065012 L NO20065012 L NO 20065012L NO 20065012 A NO20065012 A NO 20065012A NO 20065012 A NO20065012 A NO 20065012A NO 20065012 L NO20065012 L NO 20065012L
Authority
NO
Norway
Prior art keywords
processes
preparation
alkyl
compound
optionally substituted
Prior art date
Application number
NO20065012A
Other languages
English (en)
Inventor
Hitoshi Kubota
Yoshinori Nakamura
Takanori Higashijima
Yasuo Yamamoto
Kozo Oka
Shigeki Igarashi
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of NO20065012L publication Critical patent/NO20065012L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

Forbindelse med formel (I): hvor R1 er alkoksykarbonyl; R2 er alkyl; R3 er hydrogen; R4 er alkylen; R5 er en eventuelt substituert heterosyklisk gruppe; R6 , R7 og R8 er uavhengig av hverandre hydrogen, alkyl eller alkoksy; R10 er en eventuelt substituert aromatisk ring; eller et farmasøytisk akseptabelt salt av forbindelsen, som har en inhiberende aktivitet mot kolesterylestertransferprotein (CETP).
NO20065012A 2004-04-02 2006-11-01 Tetrahydronaftyridin-derivater og fremgangsmate for fremstilling av disse NO20065012L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004109551 2004-04-02
PCT/JP2005/006895 WO2005095395A2 (en) 2004-04-02 2005-04-01 Tetrahydronaphthyridine derivatives as cholesteryl ester transfer protein inhibitors

Publications (1)

Publication Number Publication Date
NO20065012L true NO20065012L (no) 2006-12-28

Family

ID=35064445

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065012A NO20065012L (no) 2004-04-02 2006-11-01 Tetrahydronaftyridin-derivater og fremgangsmate for fremstilling av disse

Country Status (18)

Country Link
US (1) US7781443B2 (no)
EP (1) EP1732924B1 (no)
JP (1) JP4633731B2 (no)
KR (1) KR100874623B1 (no)
CN (1) CN100441579C (no)
AR (1) AR048362A1 (no)
AU (1) AU2005228291B2 (no)
BR (1) BRPI0509588A (no)
CA (1) CA2560008C (no)
IL (1) IL178194A0 (no)
MX (1) MXPA06011416A (no)
MY (1) MY139887A (no)
NO (1) NO20065012L (no)
NZ (1) NZ550267A (no)
RU (1) RU2356902C2 (no)
TW (1) TWI345568B (no)
WO (1) WO2005095395A2 (no)
ZA (1) ZA200607782B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005014955D1 (de) * 2004-03-26 2009-07-30 Lilly Co Eli Verbindungen und verfahren zur behandlung von dyslipidämie
WO2006069162A1 (en) 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
CN103102303B (zh) 2004-12-31 2015-10-28 雷迪博士实验室有限公司 作为cetp抑制剂的苄胺衍生物
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
JP4681526B2 (ja) * 2005-09-29 2011-05-11 田辺三菱製薬株式会社 医薬組成物
JP2009512715A (ja) 2005-10-21 2009-03-26 ノバルティス アクチエンゲゼルシャフト レニン阻害剤と抗異脂肪血症剤および／または抗肥満症剤の組み合わせ
US7652023B2 (en) 2005-11-23 2010-01-26 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7790770B2 (en) 2005-11-23 2010-09-07 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
PE20071025A1 (es) * 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
US7750019B2 (en) 2006-08-11 2010-07-06 Kowa Company, Ltd. Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
US7790737B2 (en) 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors
DK2149563T3 (en) 2007-04-13 2015-02-02 Kowa Co Novel pyrimidine compound with dibenzylaminstruktur, and medicine comprising the compound
AU2008324243B2 (en) * 2007-11-05 2012-03-08 Novartis Ag 4-benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
EP2404901B1 (en) * 2007-12-03 2013-05-22 Novartis AG 1,2-Disubstituted 4-benzylamino-pyrrolidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
ES2617868T3 (es) 2008-08-22 2017-06-20 Baxalta GmbH Derivados de carbonato de bencilo poliméricos
EP2473055A4 (en) * 2009-09-04 2013-02-13 Univ Vanderbilt ALLOSTERIC MGLUR4 POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTIONS
MY180184A (en) * 2009-11-27 2020-11-24 Adverio Pharma Gmbh Method for producing methyl-{4,6-diamino-2-[1-(2-fluorobenyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate and its purification for use thereof as pharmaceutical substance
JPWO2012105574A1 (ja) * 2011-01-31 2014-07-03 国立大学法人 長崎大学 光学活性化合物又はその塩の製造方法
KR101774223B1 (ko) 2011-08-18 2017-09-12 닥터 레디스 레보러터리즈 리미티드 콜레스테릴 에스테르-전달 단백질(cetp) 억제제인 치환된 헤테로시클릭 아민 화합물
JP6140168B2 (ja) 2011-09-27 2017-05-31 ドクター レディズ ラボラトリーズ リミテッド アテローム性動脈硬化症の処置のために有用なコレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての５−ベンジルアミノメチル−６−アミノピラゾロ［３，４−ｂ］ピリジン誘導体
ES2599757T3 (es) 2012-01-06 2017-02-03 Daiichi Sankyo Company, Limited Sales de aducto de ácido de un compuesto de piridina sustituido como inhibidores de la proteína de transferencia de ésteres de colesterilo (PTEC)
TWI623536B (zh) 2012-01-19 2018-05-11 腫瘤療法 科學股份有限公司 １,５－萘啶衍生物與含此之ｍｅｌｋ抑制劑
US20150291596A1 (en) 2012-11-16 2015-10-15 Biocryst Pharmaceuticals, Inc. Antiviral azasugar-containing nucleosides
MX2019007120A (es) 2016-12-16 2019-09-16 Basf Se Compuestos plaguicidas.
CN111032047B (zh) * 2017-05-30 2023-10-27 多特疗法-1公司 用于生产光学活性化合物的方法
CN107245074B (zh) * 2017-06-20 2019-04-09 牡丹江医学院附属红旗医院 用于治疗脑梗死的化合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6147090A (en) * 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
DE60322665D1 (de) 2002-02-01 2008-09-18 Pfizer Prod Inc Pharmazeutische darreichungsform mit gesteuerter freigabe eines cholesterylester-transferproteininhibitors
DE602005014955D1 (de) * 2004-03-26 2009-07-30 Lilly Co Eli Verbindungen und verfahren zur behandlung von dyslipidämie

Also Published As

Publication number Publication date
MY139887A (en) 2009-11-30
EP1732924A2 (en) 2006-12-20
CN1938301A (zh) 2007-03-28
AR048362A1 (es) 2006-04-19
WO2005095395A3 (en) 2006-06-01
KR20060132966A (ko) 2006-12-22
AU2005228291B2 (en) 2008-06-26
KR100874623B1 (ko) 2008-12-17
TWI345568B (en) 2011-07-21
ZA200607782B (en) 2008-02-27
JP4633731B2 (ja) 2011-02-16
CA2560008A1 (en) 2005-10-13
MXPA06011416A (es) 2006-12-20
EP1732924B1 (en) 2012-11-28
CA2560008C (en) 2010-06-01
NZ550267A (en) 2009-08-28
WO2005095395A2 (en) 2005-10-13
RU2356902C2 (ru) 2009-05-27
BRPI0509588A (pt) 2007-09-25
US7781443B2 (en) 2010-08-24
AU2005228291A1 (en) 2005-10-13
TW200536853A (en) 2005-11-16
JP2007530444A (ja) 2007-11-01
IL178194A0 (en) 2006-12-31
RU2006138597A (ru) 2008-05-10
CN100441579C (zh) 2008-12-10
US20070032485A1 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
NO20065012L (no) Tetrahydronaftyridin-derivater og fremgangsmate for fremstilling av disse
NO20065011L (no) Tetrahydrokinolinderivater og fremgangsmate for fremstilling av disse
JO2994B1 (ar) مثبطات البروتين الناقل لاستر الكولسترول ( cetp )
TW200605883A (en) Condensed heterocycle derivative having HCV inhibitory activity
WO2008111604A1 (ja) 新規なベンジル（ヘテロサイクリックメチル）アミン構造を有するピリミジン化合物及びこれを含有する医薬
DK1533292T3 (da) Dibenzylaminforbindelse og medicinsk anvendelse deraf
MX2009012283A (es) Derivado heterociclico que contiene nitrogeno que tiene actividad inhibitoria de 11beta-hidroxiesteroide-deshidrogenasa tipo 1.
NO331165B1 (no) Derivater av dioksan-2-alkylkarbamater, fremgangsmate for fremstilling derav og anvendelse av de samme for fremstilling av medikamenter
NO20052469L (no) Inhibitorer av II-beta-hydroksysteroid-dehydrogenase type 1 og type 2.
NO20063446L (no) Tiazolderivater
NO20081464L (no) 1-heterocyklusulfonyl, 2-aminometyl, 5-(hetero-)aryl subsidiert 1-H-pyrrol-derivater som syresekresjonsinhibitorer
NO20053133L (no) Kjemiske forbindelser.
NO20092770L (no) Nye aminopyrimidinderivater som PLK1-inhibitorer
WO2008108380A3 (en) Pyrrole compounds
NO20074763L (no) (1,5-difenyl-1H-pyrazol-3-yl)oksadiazolderivater, fremgangsmate ved fremstilling derav og anvendelse av samme i terapi
AU2003254852A8 (en) Fused heterocyclic compounds as peptidase inhibitors
EP1612204A4 (en) HYDRAZONE DERIVATIVE
IN2012DN00770A (no)
MX2010010471A (es) Derivado de tetrahidroisoquinolina novedoso.
UA86077C2 (en) Cetp inhibitors
NO971687D0 (no) Diazepinoindoler som forsfodiesterase IV-inhibitorer
NO20065323L (no) 6-substituerte pyridoindolonderivater, fremstilling og anvendelse derav
ATE469156T1 (de) 3,4 diaminopyridin-derivate
NO20050572L (no) Nye benzo[b]kromeno-naftyridin-7-on- og pyrano[2',3':7,8]kino[2,3-b]kinoksalin-7-on-forbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20045540L (no) Nye 3-(4-okso-4H-kromen-2-yl)-(1H)-kinolin-4-on-forbindelser, en fremgangsmate for deres fremstilling og farmasoytisk sammensetninger inneholdende dem

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application